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All pancreatic endocrine cells, producing gluca-
gon, insulin, somatostatin, or PP, differentiate
from Pdx1+ progenitors that transiently express
Neurogenin3. To understand whether the com-
petence of pancreatic progenitors changes
over time, we generated transgenic mice ex-
pressing a tamoxifen-inducible Ngn3 fusion
protein under the control of the pdx1 promoter
and backcrossed the transgene into the
ngn3/ background, devoid of endogenous
endocrine cells. Early activation of Ngn3-ERTM
almost exclusively induced glucagon+ cells,
while depleting the pool of pancreas progeni-
tors. As from E11.5, Pdx1+ progenitors became
competent to differentiate into insulin+ and PP+
cells. Somatostatin+ cells were generated from
E14.5, while the competence to make gluca-
gon+ cells was dramatically decreased. Hence,
pancreas progenitors, similar to retinal or corti-
cal progenitors, go through competence states
that each allow the generation of a subset of cell
types. We further show that the progenitors ac-
quire competence to generate late-born cells in
a mechanism that is intrinsic to the epithelium.
INTRODUCTION
The pancreas is an organ performing vital exocrine and
endocrine homeostatic functions. The endocrine pan-
creas consists of the scattered islets of Langerhans, dis-
tinct vascularized structures nested in the pancreatic
mesenchyme between exocrine acini. The islets contain
the insulin (b)-, glucagon (a)-, somatostatin (d)-, and pan-
creatic polypeptide (PP)-secreting cells, and are thus cen-Develotral players in glucose homeostasis. Exocrine and endo-
crine cells have a common embryonic origin, namely,
a subset of endodermal cells, which start to express the
gene pdx1 around embryonic day (E) 8.5 in the mouse
(Gu et al., 2002). While pdx1 expression is dispensable
for primary budding of the pancreas, it is thereafter neces-
sary throughout development for proper growth and dif-
ferentiation of the organ (Ahlgren et al., 1996, 1997;
Bhushan et al., 2001; Hale et al., 2005; Offield et al.,
1996). The first sign of differentiation occurs as a few glu-
cagon+ cells differentiate around E9.5 in the dorsal pan-
creas. The first insulin+ cells, expressing high levels of
pdx1 (Ohlsson et al., 1993), do not appear until E12.5,
but their numbers then increase exponentially beginning
at E14.5 (Herrera et al., 1991). Somatostatin+ cells can
be detected next, followed by PP+ cells. As they differen-
tiate, endocrine cells migrate out of the epithelium of the
branching pancreas and form interstitial clusters, which
do not, however, assemble into mature islets until E18.5
(Herrera et al., 1991).
Seminal work by Herrera first demonstrated that, while
the mature a and b lineages develop independently, the
b and PP lineages are ontogenetically related (Herrera,
2000; Herrera et al., 1994). Subsequent lineage studies
by Gu et al. (2002) established that all endocrine cell types
derive from progenitors expressing the bHLH transcrip-
tion factor Neurogenin3 (Ngn3). The expression of ngn3
appears as early as E9 in some Pdx1+ cells of the dorsal
pancreas bud, peaks around E15.5, but is undetectable
in the adult pancreas (Apelqvist et al., 1999; Gradwohl
et al., 2000; Jensen et al., 2000; Schwitzgebel et al.,
2000). Ngn3+ endocrine progenitors have a limited mitotic
potential, and ngn3 expression is turned off in differenti-
ated hormone-positive cells (Gradwohl et al., 2000; Jen-
sen et al., 2000; Maestro et al., 2003; Schwitzgebel
et al., 2000). Loss-of-function experiments have demon-
strated that ngn3 is necessary for the specification of all
pancreatic endocrine subtypes (Gradwohl et al., 2000).
Conversely, gain-of-function studies showed its ability topmental Cell 12, 457–465, March 2007 ª2007 Elsevier Inc. 457
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Schwitzgebel et al., 2000; Grapin-Botton et al., 2001;
Heremans et al., 2002).
Hence, the bHLH transcription factor, Ngn3, behaves
analogously to proneural genes (Bertrand et al., 2002): it
is necessary and sufficient to initiate the development of
endocrine lineages in an endodermal context, and it pro-
motes the generation of progenitors that are committed
to endocrine differentiation (Gu et al., 2002). The role of
bHLH genes in the regulation of progenitor competence
and cell fate determination has been well studied in the
CNS (Bertrand et al., 2002; Livesey and Cepko, 2001). In
the retina, these studies have led to the ‘‘competence
model,’’ which proposes that multipotent retinal progeni-
tors pass through a series of competence states, during
each of which the progenitors are competent to produce
a subset of retinal cell types. In the cortex, however,
a model of progressive restriction of pluripotent progeni-
tors over time has been proposed (Desai and McConnell,
2000).
These observations prompted us to investigate whether
the competence of pancreatic progenitors to make the dif-
ferent endocrine lineages changes as development prog-
resses. We generated transgenic ‘‘addback’’ mice, en-
abling us to achieve temporal control of Ngn3 activity in
the pancreas. Our experiments showed that insulin+ cells
can be induced in vivo by Ngn3, and demonstrated over-
lapping windows of competence to generate different en-
docrine subtypes. We further performed homochronic and
heterochronic recombination of mesenchyme and epithe-
lium in vitro to demonstrate that changes in competence
are autonomous to the epithelium.
RESULTS AND DISCUSSION
Transgenic Mice Expressing a Tamoxifen-Inducible
Form of Ngn3 in the Pancreas
To generate an inducible form of Ngn3, we fused it to
a widely used mutated form of the estrogen receptor
(ERTM), which can only be activated by the estrogen an-
tagonist tamoxifen (TM) (Hayashi and McMahon, 2002).
In order to specifically express this inducible protein in
the pancreas, it was put under the transcriptional control
of the mouse pdx1 promoter (Gannon et al., 2001), while
addition of an ires-nGFP sequence allowed direct tracing
of cells expressing the pdx1-ngn3-ERTM-ires-nGFP
transgene (Figure 1A). Six transgenic lines were estab-
lished, and two of them, exhibiting low (LO) and high (HI)
levels of transgene expression, were kept for further anal-
ysis (Figure 1). In both lines, the expression of the pdx1-
ngn3-ERTM-ires-nGFP transgene faithfully reproduced
the endogenous pdx1 expression pattern (see Figure S1
in the Supplemental Data available with this article online).
In order to confirm the TM responsiveness of the Ngn3-
ERTM fusion protein in vivo, we investigated its subcellular
localization by immunostaining with an antibody raised
against mouse Ngn3 (Figure 1). In the absence of TM, in
the LO line, cells expressing the transgene exhibited a faint
Ngn3-ERTM cytoplasmic signal, distinguishable from the458 Developmental Cell 12, 457–465, March 2007 ª2007 Elsevihigh endogenous nuclear Ngn3 staining (compare Figures
1E–1G to Figures 1B–1D). In the HI line, however, even in
the absence of TM, most nGFP+ cells exhibited cytoplas-
mic and nuclear Ngn3-ERTM staining, possibly reflecting
a saturation of the cytoplasm retention machinery (Figures
1K–1M). Functional experiments (see below) show that, in
spite of the presence in the nucleus, very little activity is
Figure 1. TM-InducedNuclearTranslocationof theNgn3-ERTM
Fusion Protein
(A) Scheme of the transgene. Confocal images of sections of dorsal
pancreas buds from E9.5 embryos of WT (B–D), LO (E–J, Q, R), and
HI (K–P, S, T) lines, untreated (B–G, K–M, Q, S) or treated with 2 mg
TM at E8.7 (H–J, N–P, R, T). Scale bar, 50 mm.er Inc.
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genic embryos induced with TM 20 hr before dissection,
as it had previously been shown that a TM-activated
ERTM fusion remains in the nucleus for at least 24 hr (Hay-
ashi and McMahon, 2002). As expected, in both trans-
genic lines, TM treatment induced cytoplasmic depletion
and nuclear translocation of the Ngn3-ERTM protein (Fig-
ures 1H–1J and 1N–1P). Note that, in the LO line, the inten-
sity of the nuclear Ngn3-ERTM staining remained appar-
ently below the endogenous Ngn3 signal (Figures 1B
and 1H). In contrast, in the HI line, all nuclei exhibited
very strong Ngn3 immunoreactivity, in the range of or
above endogenous Ngn3+ cells (Figures 1B and 1N).
Western blotting on E11.5 pancreas extracts indeed con-
firmed a 2-fold difference in active Ngn3-ERTM protein
between the two lines (data not shown).
To demonstrate that TM treatment not only induced nu-
clear translocation of the Ngn3-ERTM protein, but also re-
sulted in its functional activation, pregnant female mice
were injected with TM at E8.7, just after the onset of
pdx1-ngn3-ERTM-ires-nGFP expression, and transgenic
embryos were analyzed at E12.5. Hypoplasia was ob-
served in both LO and HI lines, as previously observed
with a pdx-ngn3 transgene, in which pdx1 promoter is nat-
urally activated at the same time (Apelqvist et al., 1999;
Gradwohl et al., 2000; Jensen et al., 2000; Schwitzgebel
et al., 2000). Our results show that Ngn3-ERTM can drive
Pdx1+ cells out of the cell cycle (Supplemental Results
and Figure S2D).
Backcross of pdx-1-ngn3-ERTM-ires-nGFP+
into the ngn3/ Background
To precisely assess the effect of Ngn3-ERTM activation on
endocrine differentiation, the LO and HI pdx1-ngn3-ERTM-
ires-nGFP transgenic lines were each separately back-
crossed into the ngn3/ background (Gradwohl et al.,
2000). The ngn3+/ embryos, indistinguishable from
wild-type littermates (Gradwohl et al., 2000), were used
as controls. Endocrine differentiation was quantified by
immunohistochemistry on serial sections encompassing
the entire dorsal pancreas. We first established how
much background endocrine differentiation occurred in
pdx1-ngn3-ERTM-ires-nGFP+;ngn3/ embryos in the ab-
sence of any TM treatment. In the dorsal pancreas of un-
treated pdx-1-ngn3-ERTM-ires-nGFP+;ngn3/ embryos
of the HI and LO lines, a few endocrine cells were found
(Figure 2A). This low percentage of leakiness was hence-
forth subtracted as background. Pregnant females were
injected with a single dose of 2 mg TM at E8.7, E10.5,
E12.5, or E14.5. In other in vivo systems, TM-dependent
activation has been shown to occur as early as 6 hr after
injection and to last for up to 48 hr (Gu et al., 2002; Kroll
et al., 2003). TM itself, as well as its active metabolite, 4-
hydroxy-TM (4OHTM), has a short plasma half-life in the
mouse (12 and 6 hr, respectively [Robinson et al., 1991]),
which we confirmed in our transgenic mice by the lack
of any visible hypoplastic effect of TM injection 1 day be-
fore the onset of pdx1 expression, at E7.5 (data not
shown). In most of our experiments, the time interval be-Develotween TM injection and analysis varied. This had no influ-
ence on the ratio between endocrine cell types, except in
one instance that is discussed, and validated in a subset
of experiments (E14.5 +TM E8.7 versus E18.5 +TM E8.7
and E16.5 +TM E14.5 versus E18.5 +TM E14.5).
Activation of Ngn3-ERTM at E8.7 Induces
Glucagon+ Cells
Treating pdx-1-ngn3-ERTM-ires-nGFP+;ngn3/ embryos
with TM at E8.7 almost exclusively resulted in the induc-
tion of glucagon+ cells by E14.5 (Figures 2 and 3). These
cells were arranged in conspicuous, centrally located
clusters (Figures 2B and 2C), a phenotype reminiscent of
pdx1-ngn3 mice (Apelqvist et al., 1999; Schwitzgebel
et al., 2000). In the LO line, 30% less glucagon+ cells
were induced than in the HI line. These cells were nGFP,
hence Pdx1, as expected for cells that normally turn off
the pdx1 promoter (Gannon et al., 2001; Ohlsson et al.,
1993). Moreover, upon closer examination, we found
that 30% of these early induced glucagon+ cells coex-
pressed very low levels of insulin (Figures 2A and 2B0).
Such double-positive cells were not described in pdx1-
ngn3 mice, possibly due to the very low levels of insulin
(Apelqvist et al., 1999; Schwitzgebel et al., 2000), but
have been described before in early rat and mouse pan-
creas (Jackerott et al., 1996; Myrsen-Axcrona et al.,
1997; Teitelman et al., 1993; Upchurch et al., 1994). Al-
though these double-positive cells normally disappear
during development and do not measurably contribute
to the adult organ (Herrera, 2000; Herrera et al., 1994),
some could still be found at E18.5 (Figure 2C0). Unfortu-
nately, this phenotype could not be analyzed after birth,
since TM-injected females rarely carried pregnancies to
term. Based on the fact that the early insulin+ cells never
expressed Pdx1, and were always insulinlow/glucagon+,
they were not counted as ‘‘mature’’ insulin+ cells. In the
HI line, in contrast to the massive induction of glucagon+
cells following early TM activation, absolutely no Pdx1+ in-
sulin+ cells were induced above background (Figure 2A).
Sparse somatostatin- and PP-positive cells were induced
upon Ngn3-ERTM activation in the E8.7 Pdx1+ pancreatic
epithelium, but were not significantly above background.
Hence, at least in the E8.7 pancreatic epithelium, the
level of active Ngn3-ERTM does not determine the endo-
crine cell type induced by TM. It does, however, determine
the number of cells shunted into the endocrine pathway,
as 1.4-fold less glucagon+ cells were induced at E8.7 in
the LO line. Thus, our results suggest a threshold mecha-
nism rather than a graded response of pancreas progeni-
tors to different concentrations of Ngn3.
The Pancreas Acquires the Competence to Make
Insulin+ and PP+ Cells Between E10.5 and E12.5
Whereas at E8.7 the pancreas can be described as a pro-
spective domain of the primitive gut expressing pdx1, at
E10.5 it has grown to a conspicuous bud of Pdx1+ cells,
normally surrounded by a cap of glucagon+ cells. Activat-
ing the Ngn3-ERTM protein at E10.5 in the HI line resulted
in the highest number of induced endocrine cells observedpmental Cell 12, 457–465, March 2007 ª2007 Elsevier Inc. 459
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(A) Quantification of endocrine cells induced after injection of TM. Results are expressed as the mean ± SEM of total number of immunopositive cells
per dorsal pancreas. At E18.5, dorsal and ventral pancreas were not discriminated, and the entire pancreas was used. Numbers within parenthesis
refer to sample size (n). TM-induced experimental groups were compared to the appropriate NO TM control group by the parametric Dunnett test.
*p% 0.05; **p% 0.01; ***p% 0.001. TM injections at E10.5 and E14.5 were only performed in the HI family. nd, not determined; n.s., not significant;
gluc, glucagon; ins, insulin; som, somatostatin. aControl (CTR) group includes untreated pdx1-ngn3-ERTM-ires-nGFP+;ngn3+/ embryos from the HI
line and nontransgenic ngn3+/ embryos treated with TM at E12.5. bNumber of glucagon/insulin double-positive cells is expressed as a percentage of
the total number of glucagon+ cells. cOnly nGFP+ (i.e., Pdx1+) insulin+ cells are taken into account. dTo calculate this percentage, only transgenic
control embryos were taken into account (n = 3).
(B–C0) Glucagon+ cell clusters induced by TM at E8.7 in the HI line, shown at E14.5 (B, B0 ) and persisting at E18.5 (C, C0). Low levels of insulin coex-
pression in a subset of glucagon+ cells assayed by Apo Tome (B0, C0).Pdx1 is markedly downregulated in the pancreatic core at E14.5 (B), but is highly
expressed at the tip of branches at E14.5 (B) and in acini at E18.5 (C).
(D–G) Endocrine cells induced after TM injection at E12.5 in the HI line: (D) glucagon-, (E) insulin-, (F) somatostatin-, and (G) PP-positive cells. Con-
secutive sections are shown.by us at E14.5 (Figure 2A). The absolute increase in endo-
crine cell numbers most likely mirrors the peak activity of
pdx1 promoter at this stage. The major cell type produced460 Developmental Cell 12, 457–465, March 2007 ª2007 Elsevwhen activating Ngn3-ERTM at E10.5 was still glucagon+
(83% of the total number of cells induced above back-
ground [Figure 3]), but the contribution of glucagon/insulinier Inc.
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duced Endocrine Cell Types in the HI
Line
The graph was generated with the values cor-
rected for background. Error bars represent ±
SEM.coexpressing cells was halved (15% of total glucagon+). In
stark contrast with earlier Ngn3-ERTM activation, after
E10.5 the pancreas acquired the competence to make
Pdx1+/insulinHI cells, amounting to almost 10% of induced
endocrine cells (Figure 3). This coincided with a significant
increase in induced PP+ cells (Figures 2A and 3).
After E12.5, there was a marked drop in the contribution
of induced glucagon+ cells (45.6%), and less than 1% of
these glucagon+ cells coexpressed insulin (Figures 2D
and 3). The contribution of insulin+ and PP+ cells further in-
creased to 19.5% and 34%, respectively (Figures 2E, 2G,
and 3). There was still no noticeable induction of somato-
statin+ cells over background. The capacity to induce any
endocrine cells above background was completely lost at
E12.5 in the LO line (even with 4 mg TM). The pdx1 pro-
moter activity is markedly downregulated after E12.5 in
the pancreatic core, where endogenous Ngn3+ cells nor-
mally arise. This could explain the steady decrease in
the total number of endocrine cells induced in HI embryos
from E10.5 to E14.5 and the lack of responsiveness in the
LO line at E12.5, when pancreatic core cells may not ex-
press enough Ngn3-ERTM to differentiate. Insulin+ cells
were found to differentiate above background in E12.5
LO pancreas explants induced in vitro with 1 mM 4OHTM
(data not shown), further suggesting a threshold mecha-
nism rather than a graded response of pancreas progeni-
tors to different concentrations of Ngn3.
The Competence to Make Glucagon+ Cells
Is Dramatically Reduced after E14.5, while the
Competence to Form Somatostatin+ Cells Appears
After injection of TM at E14.5, the relative proportion of in-
duced insulin+ cells analyzed at E16.5 plateaued at 17.5%
(versus 19.5% for TM E12.5). PP+ cells were the major cell
type induced (Figure 2A). Although PP+ cells are normally
a minor population of the newborn and adult endocrine
pancreas, Herrera (2000) showed that beta cells transiently
express PP during their ontogeny. Hence, we hypothe-
sized that, at E16.5, we were capturing cells transiently ex-
pressing PP before becoming beta cells. In agreement with
this hypothesis, insulin+ cells increased by E18.5, while
PP+ cells decreased, suggesting that it takes severalDevelopdays to go through the transient PP+ phase. Significant in-
duction of somatostatin+ cells was observed for the first
time at E14.5 (11% of control). The competence to induce
glucagon+ cells was not significantly above background at
E16.5, but, when analyzed at E18.5, 10% glucagon+ cells
were observed. This uncertainty resulting from the leaki-
ness of the transgene lead us to clarify, in a more direct
manner, whether glucagon+ cells were still generated after
E14.5. We crossed mice in which Cre-ER is inserted in the
Ngn3 locus (G. Gu, unpublished data) with R26R-YFP mice
(Srinivas et al., 2001). Cells that were expressing Ngn3 at
the time of TM injection could be traced with this system
where Cre recombinase deletes a stop codon flanked
by LoxP sites and, therefore, permanently activates YFP
expression. Upon injection of 2 mg TM at E14.5 12% ±
1.4% of YFP+ cells were glucagon+, 41% ± 2.8% were in-
sulin+, 33% ± 3.2% were PP+, and 14% ± 1.7% were so-
matostatin+ at E18.5, confirming that there is still a minimal
competence to generate glucagon+ cells at E14.5. This is
compatible with a plateau of glucagon+ cells or glucagon
content observed by others after the ‘‘secondary transi-
tion’’ (Herrera et al., 1991; Pictet et al., 1972).
Since pdx-1-ngn3-ERTM-ires-nGFP was still expressed
at high levels at the tips of branches at E14.5 (Figure 2B),
we also sought to determine whether Ngn3-ERTM activa-
tion at this stage could perturb the differentiation of acinar
cells. Ngn3+ cells at the level of terminal end buds did not
turn down amylase expression, neither did they express
endocrine hormones, suggesting their commitment to
the exocrine lineage (data not shown).
Taken together, our experiments show that the rescue
of Ngn3 activity by the transgene allows the genera-
tion of all endocrine cell types, contrary to other ngn3 gain-
of-function models (Apelqvist et al., 1999; Dominguez-
Bendala et al., 2005; Schwitzgebel et al., 2000). Our
results conclusively show that the competence of the
Pdx1+ epithelium changes as development progresses.
This change in competence determines the type of endo-
crine cells that can differentiate upon Ngn3-ERTM activa-
tion, rather than glucagon+ being a ‘‘default fate’’
(Schwitzgebel et al., 2000). Previous experiments have
documented an exponential increase in pancreaticmental Cell 12, 457–465, March 2007 ª2007 Elsevier Inc. 461
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Explants to 4OHTM
(A) The dorsal pancreas bud of pdx1-ngn3-
ERTM-ires-nGFP+;ngn3/ embryos was ex-
planted at E10.5 and E14.5. The epithelium
was dissociated from the mesenchyme and
associated with stage-matched or hetero-
chronic mesenchyme on filters. After 5 or
16 hr, 4OHTM (1 mM) was added for 16 hr. Ex-
plants were further cultured for 48 h after
4OHTM withdrawal to allow differentiation of
endocrine cells.
(B) The recombined E10.5 explants at culture
start (day 0 [d0]), after 1 day (d1), and at the
time of fixation (d2.5). E10.5 epithelium ex-
presses transgenic GFP and expands during
the first day of culture.
(C) Representative sections of 4OHTM-treated
E10.5 epithelium and mesenchyme explants,
which have a rather flat 3-D structure. Cells ex-
pressing insulin + Pdx1 (top panel, left insert),
insulin + glucagon (top panel, right insert), glu-
cagon only (top panel), PP + Pdx1/nGFP (mid-
dle panel) and somatostain + Pdx1/nGFP (bot-
tom panel) are shown. At this stage, Pdx1
marks all epithelial cells, except glucagon+
cells. Scale bar, 100 mm.
(D) Percentage endocrine cell of each type in
different conditions. Error bars represent ±
SEM.immunoreactive insulin in the rat (termed the ‘‘secondary
transition’’ [Pictet and Rutter, 1972]), or in the number of
insulin+ cells at E15.5 in the mouse (Herrera et al., 1991).
In this study, we observed that the competence to gener-
ate insulin+ cells arises prior to the secondary transition.
The Competence to Form Insulin+ Cells Is Intrinsic
to the Epithelium
Progenitors become able to differentiate into insulin+ cells
between E10.5 and E12.5. A second shift in competence
occurs between E12.5 and E14.5, as pancreas progeni-
tors become able to form somatostatin+ cells. These
changes in competence may be cell autonomous, intrinsic
to the epithelium, or controlled by the mesenchyme. In
order to investigate the role of the mesenchyme in the
competence change, we performed epithelium/mesen-
chyme recombination experiments with either stage-
matched or heterochronic mesenchyme. The epithelium
of E10.5 pdx-1-ngn3-ERTM-ires-nGFP+;ngn3/ pan-
creata was dissected, reassociated with mesenchyme,
and cultured at the air-liquid interface. 4OHTM was added
to the culture medium 5 hr after reassociation, when the
mesenchyme had surrounded the epithelium (Figures 4A
and 4B). 4OHTM was withdrawn from the medium after
16 hr, when the explant had reached the equivalent of
E11.25. The numbers of glucagon-, insulin-, PP-, somato-
statin-, and nGFP/Pdx1-expressing cells were counted on462 Developmental Cell 12, 457–465, March 2007 ª2007 Elsevserial sections encompassing the entire explant 2 days
after 4OHTM withdrawal (Figure 4). Cell counts are pro-
vided in Table S1, and sections of each type of explants
are shown in Figure S3. The background differentiation
in the absence of 4OHTM was subtracted. In these condi-
tions, Ngn3 translocation induced massive differentiation
of glucagon+ cells, but no other cell type, including gluca-
gon+/insulinlow cells (Figure 4D). This experiment, in which
the window of transgene activation is more tightly con-
trolled than in vivo, suggests that only glucagon+ cells dif-
ferentiate before E11.25. When E14.5 pancreata were
treated similarly, PP+ and insulin+ cells represented 80%
of endocrine cells, somatostatin+ cells 15%, and gluca-
gon+ cells less than 5%, mimicking the in vivo data
(Figure 4D). When E14.5 mesenchyme was wrapped
around the E10.5 epithelium, the latter maintained its abil-
ity to massively differentiate into glucagon+ cells, but other
cell types were not observed (Figure 4D). These experi-
ments conclusively demonstrate that the E14.5 mesen-
chyme does not promote insulin/PP cell differentiation,
nor block glucagon-cell differentiation.
In contrast, when E10.5 epithelium and mesenchyme
were left in culture for 16 hr instead of 5 hr prior to
4OHTM induction, numerous cells expressing either insu-
linlow/glucagon+ or insulin+/Pdx1+ were observed, as well
as PP+ cells (Figure 4D). This effect was not dependent
on the stage of the recombined mesenchyme (E10.5 orier Inc.
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cutes the shift of competence in vitro, and that this shift
is not instructed by the mesenchyme. They also suggest
that the epithelium becomes competent to differentiate
into insulin+ and PP+ cells around E11.25. In support of
this, when E11.5 buds were put in culture and induced im-
mediately with 4OHTM for 16 hr, insulinlow/glucagon+ or in-
sulin+/Pdx1+ cells were also induced (Table S1). Although
the absolute number of glucagon+ cells did decrease in the
E10.5 pancreas associated with mesenchyme for 16 hr
prior to 4OHTM addition, this effect may be due to reduced
Pdx1 expression after longer culture periods rather than
a true reduction of the competence to form glucagon+
cells. These experiments do not rule out that mesenchymal
factors present at all stages may permit insulin-cell differ-
entiation. This could not be addressed, as E10.5 epithe-
lium could not be cultured in isolation in our system.
Conclusions
Together, our results show that, similar to retinal or cortical
neural progenitors, pancreas endocrine progenitors are
committed to generate different endocrine cell types at dif-
ferent stages. Unlike in the retina, in the pancreas, one sin-
gle bHLH proneural protein, Ngn3, is able to trigger the dif-
ferentiation of all endocrine cell types. Our studies argue
against a prominent role for Ngn3 dosage in determining
cell type allocation. Although it is possible that heteroge-
nous Pdx1+ progenitors biased to specific endocrine sub-
types do exist and are differentially selected at different
time points, the total absence of insulin+ cell induction be-
fore E10.5 suggests that a b-cell-biased progenitor popu-
lation does not exist at all before this time point. We do fa-
vor an epithelium-autonomous mechanism through which
pancreas progenitors, or a subset of those, acquire the
competence to give rise to b cells. Heterochronic trans-
plants in the cortex show that neural progenitors respond
to extrinsic cues that restrict their differentiation potential
(Desai and McConnell, 2000; Frantz and McConnell,
1996; McConnell and Kaznowski, 1991). In the retina, sim-
ilar experiments also show that, when placed in a later-
stage embryonic environment, early progenitors are un-
able to generate early-born amacrine and ganglion cells;
however, there is also evidence for an intrinsic acquisition
of the ability to form rod cells (Belliveau and Cepko, 1999;
Belliveau et al., 2000; Morrow et al., 1998; Rapaport et al.,
2001). Technological advances will be needed to maintain
single pancreatic endocrine progenitors in culture and in-
vestigate whether they can execute the competence
change in a cell-autonomous manner, or whether, as in
the cortex, other epithelial cell types send extrinsic cues.
EXPERIMENTAL PROCEDURES
Cloning of the pdx1-ngn3-ERTM-ires-nGFP Transgene
To construct pdx1-ngn3-ERTM-ires-nGFP, the mouse Ngn3 coding se-
quence was cloned downstream of a 5.15 kb fragment containing the
mouse pdx1 promoter and a heat shock protein minimal promoter
(hsp68) (Gannon et al., 2001). The rabbit bglobin1 intron and polyade-
nylation sequences were added (Herrera, 2000). Details of the con-
struction and initial activity tests are provided as Supplemental Data.DevelopMice
For TM treatment in vivo, pregnant females were injected intraperito-
neally with 200 ml of a 10 mg/ml TM (Sigma) solution in corn oil (Sigma),
offering the best compromise between efficiency of activation and
embryo viability (Gu et al., 2002; Hayashi and McMahon, 2002). TM-
injected mice were housed individually to avoid cross contamination
(Brake et al., 2004).
Generation of transgenic mice followed standard procedures (Her-
rera, 2000). Briefly, the pdx1-ngn3-ERTM-ires-nGFP fragment was in-
jected into fertilized oocytes derived from superovulated B6D2F1
male and female matings. Injected oocytes were transferred to pseu-
dopregnant NMRI females, which carried them to term. Transgenic
founders were first bred to C57BL/6 (Harlan Netherlands, Horst)
mice to generate stable lines. For subsequent matings, the outbred
strain, CD1 (Harlan), was used. For genotyping, tail biopsies were lysed
in Direct PCR Lysis Reagent (Viagen Biotech) and analyzed by PCR,
with the (50-caccatggctcctcatcccttgg-30) and (50-cctcatgtctcctgaagc-
30) primers. For the ngn3 knockout locus, the primers were as de-
scribed previously (Gradwohl et al., 2000), except that all three primers
were included in a single PCR reaction.
Explants
The pdx-1-ngn3-ERTM-ires-nGFP+;ngn3+/ males were crossed with
ngn3+/ females, generating 50% transgenic pancreata, which were
explanted. Genotyping allowed the subsequent selection of pdx1-
ngn3-ERTM-ires-nGFP+;ngn3/ explants. At least three explants
from two independent experiments were used for each culture condi-
tion. The mesenchyme was separated from the dissected dorsal pan-
creatic bud with tungsten needles and the epithelium further cleaned
from mesenchyme with dispase (Figure 4A). In such conditions, less
than 10 mesenchymal cells remain attached to the epithelium. The
mesenchyme and epithelium were reassociated on a Millicell 0.4 mm
culture insert (Millipore) at the air-liquid interface and cultured in
four-well plates with M199 medium supplemented with 10% fetal bo-
vine serum (GIBCO). 4OHTM (1 mM) was added after 5 hr, after the ep-
ithelium was surrounded by mesenchyme, or after 16 hr. 4OHTM was
rinsed four times after 16 hr, and the explants were further grown for 48
hr. Expansion of the epithelial population was observed with all E10.5
explants, mostly during the first day of culture (Figure 4B).
Immunohistochemistry and Cell Quantifications
Tissue fixation and immunohistochemistry are detailed in the Supple-
mental Data. For the quantification of endocrine cells at E14.5 or E16.5,
the entire dorsal pancreas was cut in six or seven consecutive series,
respectively. For quantifications at E18.5, the entire pancreas was sec-
tioned longitudinally (i.e., parallel to the main pancreatic duct), in eight
consecutive series. The total number of endocrine cells per dorsal pan-
creas (Figure 2A) was obtained by counting immunopositive cells on
every sixth (E14.5), seventh (E16.5), or eighth (E18.5) section, and
then normalizing accordingly. Values corrected for background were
obtained by subtracting the appropriate mean ‘‘NO TM’’ value from
the individual ‘‘+TM’’ values, hence obtaining a new ‘‘+TM’’ mean,
but the same standard deviation. For explants, sections were collected
in three (E10.5) or five (E14.5) consecutive series.
For quantifications in ngn3-Cre-ER;R26R-YFP embryos, each of
a set of four consecutive sections was mounted onto four individual
slides, which were then examined for insulin, glucagon, somatostatin,
and PP expression, respectively, by immunofluorescent staining. Co-
expression of YFP and each hormone was monitored with confocal mi-
croscopy. A minimum of 100 YFP+ cells was scored for specific hor-
mone expression for each of the 4 pancreatic buds.
Supplemental Data
Supplemental Data, including additional methods, results, figures, and
tables, are available online at http://www.developmentalcell.com/cgi/
content/full/12/3/457/DC1/.mental Cell 12, 457–465, March 2007 ª2007 Elsevier Inc. 463
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